GVHD Management in Europe: Expert Insights from Prof. Olaf Penack
&t=20s
Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation
The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3( local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global experts.
test
document.getElementById("video").style.height=document.getElementById("video").scr
At ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
Prof. Olaf Penack: Standardized GVHD Management in Europe and Future Strategies | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note: The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of…
Prof. Anna Sureda, President of EBMT, on China-Europe Collaboration and the Future of Cellular Therapy | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note:The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of the…
Professor Shun Lu: High Efficacy and Low Toxicity—SHR-A1811 Opens a New Era of ADC Therapy for HER2-Mutant NSCLC
At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), the China-developed HER2-directed antibody-drug conjugate (ADC) Trastuzumab rezetecan(SHR-A1811) made a striking appearance with new data from the HORIZON-Lung study: an objective response rate (ORR) of 74.5%, a median progression-free survival (PFS) of 11.5 months, and an interstitial lung disease (ILD) incidence of just 8.5%—setting new records among global studies in this space.
An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China
An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China, the International Workshop on Cell Therapy of Blood Diseases hosted by the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science (IHCAMS) and supported by the Ministry of Science and Technology of the People's Republic of China will be grandly held.
50 Years of Hematopoietic Stem Cell Transplantation: Xiaojun Huang on China’s Transformative Journey
From April 11 to 12, 2025, the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care(CPAM) held its annual academic meeting in Qingdao, Shandong…
Advancing AML Treatment in Asia: Insights from Professor Jianxiang Wang
We are thrilled to share an exclusive presentation by Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences. In this engaging session, Professor Wang delves into the groundbreaking findings of the Phase 3 Commodore study, recently published in Leukemia. This study provides critical new evidence on the efficacy of gilteritinib, a FLT3-inhibiting TKI, in treating relapsed or refractory FLT3-mutated acute myeloid leukemia (AML) among predominantly Asian patients.
